IMAXIO is an integrated
biotech company focused on immunology. It owns a pipeline of vaccines composed
marketed, clinical-stage and preclinical-stage products:
Marketed pharmaceuticals: a vaccine against human leptospirosis marketed
R&D pipeline based on the IMX313 technology platform: two
clinical-stage projects and several preclinical-stage candidates, based on an
antigen re-engineering platform to improve their immunogenicity, to develop
more effective vaccines & immunotherapies.
IMAXIO's main objective is to develop its R&D projects up to phase I /
phase II clinical trials, to be out-licensed to biopharmaceutical companies
able to push forward the related vaccines & immunotherapies development up
to phase III and commercialization. IMAXIO remains opened to new
collaborations, with partners having know-how on antigens poorly immunogenic in
therapeutic indication not already targeted by IMAXIO.
IMAXIO was created in 2000 as a spin-off of the Medical Research
Council and the University of Cambridge (United-Kingdom).